Q2 Earnings Forecast for BCRX Issued By Wedbush

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) - Wedbush issued their Q2 2025 earnings estimates for BioCryst Pharmaceuticals in a report issued on Tuesday, July 15th. Wedbush analyst L. Chico anticipates that the biotechnology company will post earnings per share of $0.02 for the quarter. Wedbush currently has a "Outperform" rating and a $18.00 price target on the stock. The consensus estimate for BioCryst Pharmaceuticals' current full-year earnings is ($0.36) per share. Wedbush also issued estimates for BioCryst Pharmaceuticals' FY2029 earnings at $1.09 EPS.

BCRX has been the topic of a number of other reports. Barclays lifted their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the stock an "equal weight" rating in a report on Wednesday, May 7th. Royal Bank Of Canada reaffirmed an "outperform" rating and set a $13.00 price target on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Wall Street Zen downgraded BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 28th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $17.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, June 25th. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, BioCryst Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.

BioCryst Pharmaceuticals Stock Down 1.0%

BioCryst Pharmaceuticals stock traded down $0.09 during mid-day trading on Thursday, reaching $8.61. 3,104,683 shares of the company's stock were exchanged, compared to its average volume of 3,033,016. The business's fifty day simple moving average is $9.95 and its 200 day simple moving average is $8.67. The firm has a market capitalization of $1.80 billion, a PE ratio of -33.12, a P/E/G ratio of 1.40 and a beta of 1.04. BioCryst Pharmaceuticals has a one year low of $6.02 and a one year high of $11.31.

Institutional Trading of BioCryst Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC bought a new stake in shares of BioCryst Pharmaceuticals during the 1st quarter valued at $32,000. GF Fund Management CO. LTD. purchased a new position in BioCryst Pharmaceuticals during the fourth quarter worth about $33,000. GAMMA Investing LLC grew its position in BioCryst Pharmaceuticals by 1,161.8% during the first quarter. GAMMA Investing LLC now owns 5,918 shares of the biotechnology company's stock worth $44,000 after buying an additional 5,449 shares in the last quarter. New Age Alpha Advisors LLC purchased a new position in BioCryst Pharmaceuticals during the first quarter worth about $62,000. Finally, Family Legacy Financial Solutions LLC purchased a new position in BioCryst Pharmaceuticals during the second quarter worth about $72,000. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.